Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.
Arvind Dasari, MD, MS, presents data from the FRESCO-2 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer, and provides insights on the clinical implications of the results.
Brian C. Grieb, MD, PhD, discusses unmet needs for patients with colorectal cancer, including the identification of novel pan-CRC biomarkers for drug development.